Therapy of adenocarcinoma of unknown primary: Are we making progress?

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 6, Issue 10, 2008, Pages 1061-1067

  Greco, F Anthony ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

Adenocarcinoma; CUP therapy; Therapy; Treatment; Unknown primary carcinoma

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IMATINIB; IRINOTECAN; LAPATINIB; METHOTREXATE; MITOMYCIN C; NAVELBINE; OXALIPLATIN; PACLITAXEL; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TOPOTECAN; TRASTUZUMAB;

ADENOCARCINOMA; ADVANCED CANCER; ARTICLE; BONE MARROW SUPPRESSION; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; COLON CARCINOMA; DRUG FATALITY; DRUG TARGETING; HUMAN; LUNG CARCINOMA; METASTASIS; OCCULT CANCER; OVERALL SURVIVAL; PANCREAS CARCINOMA; PROGNOSIS; RECTUM CARCINOMA; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA;

EID: 57449120455     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2008.0079     Document Type: Article

References (47)

1. Greco FA, Hainsworth JD. Cancer of unknown primary site. In: De Vita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 7th ed. Philadelphia: J.B. Lippincott; 2005:2213-2236.
2. Pentheroudakis G, Golfinopoulos V, Pavlidis N. Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer 2007;43:2026-2036.
3. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
4. Sandler AB, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small lung cancer. N Engl J Med 2006;355:2542-2550.
5. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-1966.
6. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metasratic colorectal cancer. J Clin Oncol 2004;22:23-30.
7. Folprecht G, Seymour MT, Saltz L, et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol 2008;26:1443-1451.
8. Bunn PA Jr. Treatment of advanced non-small-cell lung cancer with two-drug combinations. J Clin Oncol 2002;20:3565-3567.
9. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2000;346:91-98.
10. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285-4291.
11. Paccagnella A, Oniga F, Bearz A, et al. Adding gemcitabine to paclitaxel/ carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III study. J Clin Oncol 2006;24:681-687.
12. Van Cutsem E, Verslype C, Grusenmeyer PA. Lessons learned in the management of advanced pancreatic cancer. J Clin Oncol 2007;25:1949-1952.
13. Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006;24:3946-3952.
14. Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group trial E2297. J Clin Oncol 2002;20:3270-3275.
15. Altman E, Cadman E. An analysis of 1,539 patients with cancer of unknown primary site. Cancer 1986;57:120-124.
16. Hess KR, Abbruzzese MC, Lenzi R, et al. Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res 1999;5:3403-3410.
17. Holmes FF, Fouts TL. Metastatic cancer of unknown primary site. Cancer 1970;26:816-820.
18. Krementz ET, Cerise EJ, Foster DC, et al. Metastases of undetermined source. Curr Probl Cancer 1979;4:4-37.
19. Markman M. Metastatic adenocarcinoma of unknown primary site: analysis of 245 patients seen at the Johns Hopkins Hospital from 1965-1979. Med Ped Oncol 1982;10:569-574.
20. Moertel CG, Reitmeier RJ, Schutt AJ, et al. Treatment of the patient with adenocarcinoma of unknown primary site. Cancer 1972;30: 1469-1472.
21. Muir C. Cancer of unknown primary site. Cancer 1995;75:353-356.
22. Van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW, Hillen HF. Epidemiology of unknown primary tumors: incidence and population-based survival of 1285 patients in Southeast Netherlands 1984-1992. Eur J Cancer 2002;38:409-413.
23. Levi F, Te VC, Erler G, et al. Epidemiology of unknown primary tumors. Eur J Cancer 2002;38:1810-1812.
24. Tracey FA, Glass P, Roder D, et al. Unknown primary cancer in New South Wales, Sydney Cancer Institute. NSW 2008 New South Wales Central Cancer Registry. Cancer Institute NSW Web site. Available at: http://www.cancerinstitute.org.au/cancer_inst/publications/pdfs/ em-2008-01_unknown-primary-cancer.pdf. Accessed September 4, 2008.
25. Fizazi K, Schmoll HJ. Randomized trials in patients with carcinoma of an unknown primary: the past, the present, and the future. In: Fizazi K, ed. Carcinoma of an Unknown Primary Site. New York: Taylor and Francis Books LLC;2006:105-114.
26. Hainsworth JD, Erland JB, Kalman CA, et al. Carcinoma of unknown primary site: treatment with one-hour paclitaxel, carboplatin and extended schedule etoposide. J Clin Oncol 1997;15:2385-2395.
27. Greco FA, Erland JB, Morrissey LH, et al. Phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol 2000;11:211-215.
28. Greco FA, Burris HA, Litchy S, et al. Gemcitabine, carboplatin, and paclitaxel for patients with unknown primary site: a Minnie Pearl Cancer Research Network study. J Clin Oncol 2002;20:1651-1656.
29. Greco FA, Rodriguez GI, Shaffer DW, et al. Carcinoma of unknown primary Site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial. The Oncologist 2004;9:644-652.
30. Greco FA, Hainsworth JD. Cancer of unknown primary site. In: DeVita VT Jr, Hellman S, Rosenberg SA, et al. Cancer: Principles and Practice Oncology. 8th ed. Philadelphia: J.B. Lippincott; 2008:2363-2387.
31. Hainsworth JD, Spigel DR, Farley C, et al. Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: Minnie Pearl Cancer Research Network. J Clin Oncol 2007; 25:1747-1752.
32. Seve P, Ray-Coquard I, Trillet-Lenoir V, et al. Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinoma of unknown primary site. Cancer 2006;107:2698-2702.
33. Culine S, Kramar A, Saghatchian M, et al. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 2002;20:4679-4683.
34. van de Wouw AJ, Jansen RL, Griffioen AW, et al. Clinical and immunohistochemical analysis of patients with unknown primary tumour. A search for prognostic factors in UPT. Anticancer Res 2004;24:297-301.
35. Briasoulis E, Kalofonos H, Bafaloukos D, et al. Carboplatin plus paclitaxel in unknown primary cancer: a phase II Hellenic Cooperative Oncology Group study. J Clin Oncol 2000;18:3101-3107.
36. Dowell JE, Garrett AM, Shyr Y, et al. A randomized phase II trial in patients with carcinoma of an unknown primary site. Cancer 2001;91: 592-597.
37. Pittman KB, Oliver IN, Koczwara R, et al. Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide cancer trials and education collaborative study. Br J Cancer 2006;95:1309-1313.
38. Culine S, Lortholary A, Voigt JJ, et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study trial for the French Study Group on Carcinomas of Unknown Primary. J Clin Oncol 2003;21:3479-3482.
39. Balana C, Manzano JL, Moreno L, et al. A phase II study of cisplatin, etoposide and gemcitabine in an unfavorable group of patients with carcinoma of unknown primary site. Ann Oncol 2003;14:1425-1429.
40. Piga A, Nortilli R, Cetto GL, et al. Carboplatin, doxorubicin and etoposide in the treatment of tumors of unknown primary site. Br J Cancer 2004;90:1898-1904.
41. Park YH, Ryoo BY, Choi SJ, et al. A phase II study of paclitaxel plus cisplatin chemotherapy in an unfavorable group of patients with cancer of unknown primary site. Jpn J Clin Oncol 2004;34: 681-685.
42. Pouessel D, Culine S, Becht C, et al. Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site. Cancer 2004;100:1257-1261.
43. Briasoulis E, Fountzilas G, Bamias A, et al. Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a Hellenic Cooperative Group study. Cancer Chemother Pharmacol 2008;62:277-284.
44. El-Rayes BF, Shields AF, Zalupski M, et al. A phase II study of carboplatin and paclitaxel in adenocarcinoma of unknown primary site. Am J Clin Oncol 2005;28:152-156. 45 Palmeri S, Lorusso V Palmeri L, et al. Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site. Cancer 2006;1007:2898-2905.
45. Schneider BJ, El-Reyes B, Muler JH, et al. Phase II trial of carboplatin, gemcitabine and capecitabine in patients with carcinoma of unknown primary site cancer. Cancer 2007;110:770-775.
46. Berry W, Elkordy M, O'Rourke M, et al. Results of a phase II study of weekly paclitaxel plus carboplatin in advanced carcinoma of unknown primary origin: a reasonable regimen for the community-based clinic? Cancer Invest 2007;25:27-31.
47. Varadhachary G, Talantov D, Raber M, et al. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol 2008; in press.